- Home
- / TransCode Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
TransCode Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.6
2024-10-29
Market Capitalization
$9.7 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 14, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| General and administrative expense | 3.4M | 8.4M | 7.2M | 6.0M | 5.8M |
| Operating expense total | 18.7M | 15.7M | 19.2M | ||
| EBIT | (6.2M) | (18.7M) | (19.4M) | (15.7M) | (28.0M) |
| Interest income | 664.0 | 20.4K | 5.3K | 684.0 | 79.2K |
| Interest expense | 55.9K | 26.8K | |||
| Pre tax profit | (34.4M) | ||||
| Income tax expense | 53.1K | 226.1K | |||
| Net Income | (6.8M) | (17.6M) | (18.5M) | (16.8M) | (34.7M) |
| EPS | (1.3) | (103.0) | (47.1) | (52.6) |